Go Deep
ABVC BioPharma, Inc.
ABVC BioPharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,756 | -3.1 | 2.42 | 0.23 | 88.32 |
| Oct 2026 | 21,799 | -3.1 | 2.38 | 0.23 | 86.94 |
| Oct 2026 | 20,822 | -3.0 | 2.36 | 0.23 | 86.28 |
| Oct 2026 | 20,759 | -3.1 | 2.41 | 0.23 | 88.18 |
| Oct 2026 | 20,553 | -3.3 | 2.60 | 0.23 | 94.58 |
| Oct 2026 | 20,415 | -3.5 | 2.72 | 0.23 | 98.86 |
ABVC BioPharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | -795,950.0 | 0.0 |
| Net Profit | -736,934.0 | -1,560,242.0 | -3,562,944.0 | -2,042,463.0 |
| EPS | -0.0 | -0.1 | — | -0.1 |
ABVC BioPharma, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 509,589.0 | 152,430.0 | 969,783.0 | — |
| Net Profit | -7,908,554.0 | -4,902,878.0 | -7,788,050.0 | -16,423,239.0 | — |
| EPS | -0.4 | -0.4 | -1.8 | -5.2 | — |
ABVC BioPharma, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 21,062,203.0 | 7,539,907.0 | 7,784,499.0 | 9,579,574.0 | — |
| Total Liabilities | 7,764,723.0 | 6,815,948.0 | 6,531,026.0 | 6,343,435.0 | — |
| Total Equity | 11,111,861.0 | 1,226,140.0 | 1,554,110.0 | 3,098,585.0 | — |
Owes vs Owns
ABVC BioPharma, Inc. owed $0.37 for every $1 it owned in Jun 2026, down from $0.66 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.37× | 0.37× | 0.90× | 0.84× | 0.66× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ABVC BioPharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 3.5%Receivables 3.6%Fixed assets (tangible) 70.0%Long-term investments 8.9%Other assets 13.9%
How it's funded — Dec 2025
Short-term debt 7.4%Long-term debt 7.6%Payables 0.6%Other liabilities 21.3%Shareholders' equity 63.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 0.7 | 0.3 | 0.1 | 0.2 |
| Receivables | 0.8 | 1.2 | 0.8 | 1.4 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 14.7 | 1.2 | 1.4 | 1.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 1.9 | 2.3 | 2.5 | 0.8 |
| Other assets | 2.9 | 2.7 | 3.0 | 5.5 |
| Liabilities & equity | ||||
| Short-term debt | 1.6 | 1.8 | 1.8 | 1.9 |
| Long-term debt | 1.6 | 0.2 | 0.4 | 0.8 |
| Payables | 0.1 | 0.8 | 0.3 | 0.4 |
| Other liabilities | 4.5 | 4.0 | 4.1 | 3.3 |
| Shareholders' equity | 13.3 | 0.7 | 1.3 | 3.2 |
| Net tangible assets | 11.1 | 1.2 | 1.6 | 3.1 |
ABVC BioPharma, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -2,986,299.0 | -1,809,145.0 | -4,186,848.0 | -7,398,391.0 | — |
| Investing Activities | -1,208,790.0 | 0.0 | -360,186.0 | -1,721,684.0 | — |
| Financing Activities | 4,637,995.0 | 1,980,769.0 | 3,869,961.0 | 4,013,925.0 | — |